Collaborative Research: TLS: An Experimental Producer Price Index for Clinical Trials

合作研究：TLS：临床试验的实验性生产者价格指数

• 批准号: 0915677
• 负责人: Iain Cockburn
• 金额: $ 12.04万
• 依托单位: Trustees of Boston University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-15 至 2011-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0915677&HistoricalAwards=false
• 关键词: Collaborative; Research; TLS; Experimental; Producer

Project Description.This research project studies the feasibility of constructing price indexes specifically for clinical trials, an important component of healthcare R&D. Increasing health care R&D spending is an important policy issue, but changes in expenditure are very difficult to evaluate without knowing whether these increases are due to changes in the prices of inputs to biomedical research, as opposed to changes in the quantity of research being performed.Intellectual MeritThe project constructs a "price deflator" that decomposes growth in total expenditure into price and quantity components. Very few of these price indexes have been constructed specifically for scientific research, not least because R&D activities tend to be highly heterogeneous, and therefore difficult to compare meaningfully year-to-year or across different contexts. Sufficiently detailed data make it possible both to make price comparisons that hold constant factors such as the stage of clinical development, therapeutic area, and number of patients, and to control for the complexity and work burden associated with different trial designs, The methodology that is used "hedonic price analysis" has been well-established in many areas, such as constructing deflators for IT products, but not has not previously been applied to scientific research activity. These price indexes, combined with data on clinical trial activity published in public registries such as clinicaltrials.gov, allow the construction of broad-based estimates of clinical trial expenditures broken out by state, country, and type of R&D performer. Broader Impact.Along with evidence on the evolution of the price of clinical research, this project sheds light on a number of methodological issues relating to the integration of R&D investment into the national income accounts, and informs important policy debates surrounding the "outsourcing" and "offshoring" of US R&D, and the global competitiveness of American medical research establishments. Clinical trials are increasingly being performed outside traditional US academic medical centers, at physicians' offices, clinics, and provider networks, as well as by specialized for-profit entities. Moreover, trials have become increasingly global, with a single protocol collecting data from sites in many different countries. These new features of clinical trials are one example of broader changes under way in the distribution of R&D activity across geographies, actors, and institutions. This research project helps develop a better understanding of the economic forces underlying this phenomenon.This approach can be used by BEA and other agencies in developing estimates of the impact of R&D on real and nominal gross domestic product, even at the state or regional level, which is very difficult to do with current data.

项目描述：该研究项目研究专门为临床试验构建价格指数的可行性，临床试验是医疗保健研发的重要组成部分。 增加医疗保健研发支出是一个重要的政策问题，但如果不知道这些增加是否是由于生物医学研究投入价格的变化，而不是由于正在进行的研究数量的变化，则很难评估支出的变化。智力优点该项目构建了一个“价格平减指数”，将总支出的增长分解为价格和数量部分。 这些价格指数很少是专门为科学研究而构建的，尤其是因为研发活动往往高度异质，因此很难进行有意义的逐年比较或在不同背景下进行比较。 足够详细的数据使得可以在保持临床开发阶段、治疗领域和患者数量等恒定因素的情况下进行价格比较，并控制与不同试验设计相关的复杂性和工作负担。使用的“特征价格分析”已经在许多领域得到了广泛应用，例如为IT产品构建平减指数，但此前并未应用于科学研究活动。 这些价格指数与公共登记处（例如 ClinicalTrials.gov）发布的临床试验活动数据相结合，可以对按州、国家和研发执行者类型细分的临床试验支出进行广泛的估计。 更广泛的影响。除了临床研究价格演变的证据外，该项目还阐明了与将研发投资纳入国民收入账户相关的许多方法论问题，并为围绕“外包”和“外包”的重要政策辩论提供了信息。美国研发的“离岸外包”以及美国医学研究机构的全球竞争力。 临床试验越来越多地在美国传统学术医疗中心之外、医生办公室、诊所和提供商网络以及专门的营利性实体中进行。 此外，试验变得越来越全球化，单一方案从许多不同国家的站点收集数据。 临床试验的这些新特征是跨地域、参与者和机构的研发活动分布正在发生更广泛变化的一个例子。 该研究项目有助于更好地理解这一现象背后的经济力量。BEA 和其他机构可以使用这种方法来估计研发对实际和名义国内生产总值的影响，即使是在州或地区层面。这对于当前的数据来说是非常困难的。